Second-line treatment of ovarian cancer with single-agent gemcitabine

Semin Oncol. 2002 Feb;29(1 Suppl 1):9-10. doi: 10.1053/sonc.2002.31588.


Single-agent gemcitabine has been examined in several phase II trials in platinum- and paclitaxel-resistant advanced ovarian cancer. In this population, where patients are often heavily pretreated prior to the administration of gemcitabine, an acceptable dose and schedule is 800 to 1,000 mg/m(2) weekly for 3 weeks, followed by a 1-week rest. The anticipated objective response rate in the platinum/taxane-resistant population is approximately 15%. This level of activity (confirmed in several phase II trials), and the generally favorable toxicity profile for gemcitabine in this group of patients, leads to the conclusion that single-agent gemcitabine is a reasonable second-line treatment option in previously treated women with advanced ovarian cancer.

Publication types

  • Review

MeSH terms

  • Antimetabolites, Antineoplastic / therapeutic use*
  • Antineoplastic Agents
  • Cisplatin
  • Clinical Trials, Phase II as Topic
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / therapeutic use*
  • Drug Resistance, Neoplasm
  • Female
  • Humans
  • Neoplasm Recurrence, Local / drug therapy
  • Ovarian Neoplasms / drug therapy*


  • Antimetabolites, Antineoplastic
  • Antineoplastic Agents
  • Deoxycytidine
  • gemcitabine
  • Cisplatin